Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of SHR0302 tablets in active non-radiographic axial spondyloarthritis
CTR20220802Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Hengrui Therapeutics. Started Aug 2022; status: active.
02
Drugs
ivarmacitinib
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on CTR20220802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220802.